The role of C-reactive protein as a prognostic indicator in advanced cancer

Geissbuhler P, Mermillod B, Rapin CH: Elevated serum vitamin B12 levels associated with CRP as a predictive factor of mortality in palliative care cancer patients: a prospective study over five years. J Pain Symptom Manage 2000, 20:93–103. This interesting study indicates that an elevated serum B12 level is a predictive factor for mortality, independent of CRP and other factors, in palliative care. Du Clos TW: Function of C-reactive protein. Ann Med 2000, 32:274–278. Jaye DL, Waites KB: Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J 1997, 16:735–746. Yeh ET, Anderson HV, Pasceri V, Willerson JT: C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001, 104:974–975. This is an interesting article discussing the role of inflammation and CRP as predisposing to cardiovascular events. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448–454. Morrow DA, Ridker PM: C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000, 84:149–161. Di Napoli M, Papa F, Bocola V: C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001, 32:917–924. Kushner I: C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging. Cleve Clin J Med 2001, 68:535–537. s is an excellent article discussing the role of CRP as a predictor for both biologic aging and poor prognosis in many conditions. Preston T, Fearon KC, McMillan DC, et al.: Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. Br J Surg 1995, 82:229–234. McMillan DC, Wigmore SJ, Fearon KC, et al.: A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999, 79:495–500. s is an outstanding study comparing the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in patients with gastrointestinal cancer. Falus A, Meretey K: Histamine: an early messenger in inflammatory and immune reactions. Immunol Today 1992, 13:154–156. Rasmussen LA, Nielsen HJ, Sorensen S, et al.: Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis. J Am Coll Surg 1995, 181:138–144. Pelliniemi TT, Irjala K, Mattila K, et al.: Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995, 85:765–771. Tartour E, Dorval T, Mosseri V, et al.: Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994, 69:911–913. Legouffe E, Rodriguez C, Picot MC, et al.: C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin’s lymphoma. Leuk Lymphoma 1998, 31:351–357. Kodama J, Miyagi Y, Seki N, et al.: Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999, 82:107–110. is an interesting study about the role of CRP in predicting survival. Scambia G, Testa U, Benedetti PP, et al.: Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995, 71:354–356. Ljungberg B, Grankvist K, Rasmuson T: Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer 1995, 76:1435–1439. Huang A, Tsavellas G: Acute-phase protein, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 2001, 88:1128. O’Gorman P, McMillan DC, McArdle CS: Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 2000, 37:36–40. Falconer JS, Fearon KC, Ross JA, et al.: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995, 75:2077–2082. Barber MD, Fearon KC, Ross JA: Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci 1999, 96:83–87. Nozoe T, Matsumata T, Kitamura M, Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998, 176:335–338. Miyata Y, Koga S, Nishikido M, et al.: Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 2001, 58:161–164. Vesole DH, Tricot G, Jagannath S, et al.: Autotransplants in multiple myeloma: what have we learned? Blood 1996, 88:838–847. Bataille R, Boccadoro M, Klein B, et al.: C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992, 80:733–737. Mestries JC, Kruithof EK, Gascon MP, et al.: In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw 1994, 5:275–281. Cermak J, Key NS, Bach RR, et al.: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82:513–520. Harris TB, Ferrucci L, Tracy RP, et al.: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106:506–512. Baeuerle PA, Rupec RA, Pahl HL: Reactive oxygen intermediates as second messengers of a general pathogen response. Pathol Biol 1996, 44:29–35. Nelson KA, Walsh D, Sheehan FA: The cancer anorexiacachexia syndrome. J Clin Oncol 1994, 12:213–225. Walsh D, Donnelly S, Rybicki L: The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 2000, 8:175–179. s is an excellent comprehensive prospective analysis of symptoms in 1000 patients with advanced cancer. Strassmann G, Fong M, Kenney JS, Jacob CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992, 89:1681–1684. Tisdale MJ: Wasting in cancer. J Nutr 1999, 129:243S-246S. Tempfer C, Zeisler H, Sliutz G, et al.: Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997, 66:27–30. Oka M, Yamamoto K, Takahashi M, et al.: Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996, 56:2776–2780. Warren RS, Starnes HF Jr, Gabrilove JL, et al.: The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 1987, 122:1396–1400. McMillan DC, Scott HR, Watson WS, et al.: Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer 1998, 31:101–105. Kato K, Hitsuda Y, Kawasaki Y, et al.: The value of serum C-reactive protein as a survival determinant in patients with advanced non-small-cell lung cancer. Nihon Kokyuki Gakkai Zasshi 2000, 38:575–580. Wu CW, Wang SR, Chao MF, et al.: Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996, 91:1417–1422. Nomura K, Noguchi Y, Matsumoto A: Stimulation of decreased lipoprotein lipase activity in the tumor-bearing state by the antihyperlipidemic drug bezafibrate. Surg Today 1996, 26:89–94. Ohara M, Tsutsumi K, Ohsawa N: Suppression of carcass weight loss in cachexia in rats bearing Leydig cell tumor by the novel compound NO-1886, a lipoprotein lipase activator. Metabolism 1998, 47:101–105. Tsujimoto S, Kawamura I, Inami M, et al.: Cachexia induction by EL-4 lymphoma in mice and possible involvement of impaired lipoprotein lipase activity. Anticancer Res 2000, 20:3111–3116. Lavabre-Bertrand T, Exbrayat C, Liautard J, et al.: Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies. Br J Haematol 1995, 91:871–877. Yokoyama A, Kohno N, Hirasawa Y, et al.: Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clin Exp Immunol 1995, 100:325–329. Baumann H, Gauldie J: The acute phase response. Immunol Today 1994, 15:74–80. Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon KC: Acutephase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 2001, 88:255–260. s important study investigates the prognostic significance of a preoperative and postoperative acute phase protein response in relation to disease-specific mortality rate. Cooper EH, Stone J: Acute phase reactant proteins in cancer. Adv Cancer Res 1979, 30:1–44. McMillan DC, Wotherspoon HA, Fearon KC, et al.: A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg 1995, 170:319–322. Fujikawa K, Matsui Y, Oka H, et al.: Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol 1999, 162:1934–1937. Earlam S, Glover C, Fordy C, et al.: Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 1996, 14:171–175. Goransson J, Jonsson S, Lasson A: Pre-operative plasma levels of C-reactive protein, albumin and various plasma protease inhibitors for the pre-operative assessment of operability and recurrence in cancer surgery. Eur J Surg Oncol 1996, 22:607–617. Steinshamn S, Brekke OL, Waage A: Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin-6 in serum in granulocytopenic patients with fever. Br J Haematol 1995, 89:719–724. Kallio R, Bloigu A, Surcel HM, Syrjala H: C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas. Support Care Cancer 2001, 9:124–128. Heney D, Lewis IJ, Evans SW, et al.: Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis 1992, 165:886–890. Economos K, Lucci JAIII, Richardson B, et al.: The effect of naproxen on fever in patients with advanced gynecologic malignancies. Gynecol Oncol 1995, 56:250–254. Ueno H, Okada S, Okusaka T, et al.: Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000, 59:296–301.